A is for anti-angiogenic

被引：0
|
作者：
不详
机构：
来源：
NATURE MEDICINE | 2001年 / 7卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：418 / 418
页数：1
相关论文
共 50 条
  • [1] ANTI-ANGIOGENIC ISOFORMS OF VEGF - A KEY TO ANTI-ANGIOGENIC THERAPY
    Bates, D. O.
    Harper, S. J.
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3207 - 3208
  • [2] Anti-angiogenic immunotherapy
    Schoenfeld, Jonathan D.
    Dranoff, Glenn
    HUMAN VACCINES, 2011, 7 (09): : 976 - 981
  • [3] Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors
    Dey, Nandini
    De, Pradip
    Brian, Leyland-Jones
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2015, 7 (10): : 1675 - 1698
  • [4] Combination of anti-angiogenic therapy and virotherapy: Arming oncolytic viruses with anti-angiogenic genes
    Tysome, James R.
    Lemoine, Nick R.
    Wang, Yaohe
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2009, 11 (06) : 664 - 669
  • [5] Dieckol as a novel anti-proliferative and anti-angiogenic agent and computational anti-angiogenic activity evaluation
    Li, Yong-Xin
    Li, Yong
    Je, Jae-Young
    Kim, Se-Kwon
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2015, 39 (01) : 259 - 270
  • [6] Anti-angiogenic activity of tocotrienol
    Inokuchi, H
    Hirokane, H
    Tsuzuki, T
    Nakagawa, K
    Igarashi, M
    Miyazawa, T
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2003, 67 (07) : 1623 - 1627
  • [7] Anti-angiogenic properties of plaunotol
    Kawai, K
    Tsuno, NH
    Kitayama, J
    Okaji, Y
    Yazawa, K
    Asakage, M
    Yamashita, H
    Watanabe, T
    Takahashi, K
    Nagawa, H
    ANTI-CANCER DRUGS, 2005, 16 (04) : 401 - 407
  • [8] Anti-angiogenic therapy for osteosarcoma
    Quan, Gerald M. Y.
    Choong, Peter F. M.
    CANCER AND METASTASIS REVIEWS, 2006, 25 (04) : 707 - 713
  • [9] Anti-angiogenic strategies in glioblastoma
    Guillamo, J. -S.
    REVUE NEUROLOGIQUE, 2011, 167 (10) : 662 - 667
  • [10] Cancer anti-angiogenic therapy
    Shimizu, K
    Oku, N
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (05) : 599 - 605
12345